全文获取类型
收费全文 | 15339篇 |
免费 | 1332篇 |
国内免费 | 335篇 |
专业分类
耳鼻咽喉 | 113篇 |
儿科学 | 248篇 |
妇产科学 | 108篇 |
基础医学 | 1084篇 |
口腔科学 | 333篇 |
临床医学 | 2347篇 |
内科学 | 1328篇 |
皮肤病学 | 67篇 |
神经病学 | 887篇 |
特种医学 | 1069篇 |
外国民族医学 | 2篇 |
外科学 | 938篇 |
综合类 | 1881篇 |
现状与发展 | 1篇 |
预防医学 | 2647篇 |
眼科学 | 134篇 |
药学 | 2666篇 |
25篇 | |
中国医学 | 758篇 |
肿瘤学 | 370篇 |
出版年
2024年 | 11篇 |
2023年 | 280篇 |
2022年 | 380篇 |
2021年 | 707篇 |
2020年 | 796篇 |
2019年 | 670篇 |
2018年 | 592篇 |
2017年 | 595篇 |
2016年 | 594篇 |
2015年 | 587篇 |
2014年 | 1060篇 |
2013年 | 1303篇 |
2012年 | 991篇 |
2011年 | 1070篇 |
2010年 | 811篇 |
2009年 | 656篇 |
2008年 | 719篇 |
2007年 | 700篇 |
2006年 | 607篇 |
2005年 | 478篇 |
2004年 | 381篇 |
2003年 | 381篇 |
2002年 | 276篇 |
2001年 | 231篇 |
2000年 | 256篇 |
1999年 | 205篇 |
1998年 | 153篇 |
1997年 | 133篇 |
1996年 | 104篇 |
1995年 | 141篇 |
1994年 | 111篇 |
1993年 | 90篇 |
1992年 | 100篇 |
1991年 | 80篇 |
1990年 | 72篇 |
1989年 | 59篇 |
1988年 | 80篇 |
1987年 | 66篇 |
1986年 | 56篇 |
1985年 | 78篇 |
1984年 | 72篇 |
1983年 | 47篇 |
1982年 | 53篇 |
1981年 | 30篇 |
1980年 | 22篇 |
1979年 | 40篇 |
1978年 | 22篇 |
1977年 | 16篇 |
1976年 | 16篇 |
1975年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
背景 随着患者就诊下沉明显,联合家庭医生团队开展社区药学服务日益重要,但如何发挥家庭医生团队作用以满足患者社区药学服务需求仍有待进一步探索。 目的 了解上海市社区药学服务需求现状,为改进社区药学人员参与家庭医生团队开展服务的方式提供参考建议。 方法 于2020年9—12月,采用多阶段抽样法抽取349例老年慢性病患者和855例家庭医生团队主要成员〔全科医生(n=481)、护士(n=234)、公共卫生医生(n=140)〕进行问卷调查。针对老年慢性病患者的调查问卷主要内容包括基本情况、患病情况、用药情况、社区药学服务需求情况和社区药学服务利用情况。针对家庭医生团队成员的调查问卷主要内容包括基本情况、社区药学服务认知情况和社区药学服务需求情况。 结果 349例老年慢性病患者中,125例(35.8%)同时患有≥3种慢性病,305例(87.4%)每日需多次用药。用药管理类药学服务方面,"用药重整及随访"需求人数最多,为52例(14.9%),"用药随访"利用人数最多,为49例(14.0%)。用药教育类药学服务方面,"慢性病用药特殊性的普及教育"需求人数最多,为247例(70.8%),"宣传健康生活方式"利用人数最多,为33例(9.4%)。家庭医生团队成员中,全科医生、护士、公共卫生医生对药学服务的了解程度方面,分别有440例(91.5%)、202例(86.3%)、112例(80.0%)表示了解;对药师的信任程度方面,分别有302例(62.8%)、183例(78.2%)、103例(73.6%)表示非常信任;"协同医师做好药物使用遴选"服务项目的需求人数分别有359例(74.6%)、112例(47.9%)、81例(57.8%);"指导护士使用与管理药品"服务项目的需求人数分别有190例(39.5%)、153例(65.4%)、57例(40.7%)。 结论 一方面患者实际迫切需要用药管理类药学服务,另一方面患者的用药教育类药学服务需求远未得到满足。鉴于社区药学人员队伍薄弱及家庭医生团队对社区药学服务认知局限的现状,社区药学人员应通过培训团队成员,提升团队的社区药学服务认知水平及服务能力,借助团队力量及成员特性,更广泛高效地开展社区药学服务。 相似文献
2.
目的 评价美国国家电器制造协会(National Electrical Manufactures Association, NEMA)最新标准(NU 2-2018)在正电子发射型计算机断层显像/电子计算机断层显像(positron emission tomography/computed tomography, PET/CT)设备性能检测中的作用。 方法 依据最新的NEMA NU 2-2018标准,检测西门子Biograph Vision PET/CT的空间分辨率、灵敏度、散射分数、计数丢失、随机符合、飞行时间分辨率、计数丢失率和随机符合校正精度、图像质量、衰减和散射校正精度及PET与CT配准精度指标。 结果 距视野中心1 cm处横向和轴向空间分辨率分别为3.75 mm和3.76 mm;在视野中心和轴向10 cm处的灵敏度分别为16.83 kcps/MBq和16.67 kcps/MBq;放射性浓度为27.37 kBq/mL时,最大等效噪声计数率为258.26 kcps,散射分数为38.58%;系统时间分辨率为209.82 ps;图像质量模型的对比度恢复系数范围为88.9%~96.2%,背景变异系数范围为2.05%~6.80%,平均肺插件残余误差为2.43%;计数丢失和随机符合校正最大误差为3.9%;距离床板末端 5 cm 和 100 cm处,在距视野中心Y轴1 cm处,PET和CT的配准精度分别为0.46 mm和1.07 mm,在距视野中心X轴20 cm处,PET和CT的配准精度分别为1.06 mm和1.45 mm,在距视野中心Y轴20 cm处PET和CT的配准精度分别为0.85 mm和1.15 mm。 结论 NEMA NU 2-2018标准检测条件更加接近临床,能更好地反映PET/CT设备的系统性能。 相似文献
3.
目的评价由丹娜(天津)生物科技股份有限公司生产的隐球菌荚膜多糖检测试剂盒(胶体金法,考核试剂)的检测性能。方法选取隐球菌和隐球菌近缘菌及肺部感染常见菌种共28属100株菌作为研究对象,配制0.5麦氏浊度单位(0.5 M)菌液检测试剂的特异性,0.5 M阳性的菌株以10倍倍比稀释液作为灵敏度检测菌液,以2 M和4 M浓度菌液作为钩状效应检测菌液,并以美国Immuno Mycologics公司生产的隐球菌抗原检测(胶体金免疫层析法)试剂盒作为对比试剂,比较两家试剂的一致性。结果31株隐球菌属菌株中,考核试剂检测出阳性25株(新型隐球菌和格特隐球菌均为阳性),阴性6株(维多利亚隐球菌、C.dimennae和大隐球菌);16株毛孢子菌属菌株中,检测出阳性12株,阴性4株;1株Cutaneotrichosporon curvatum检测结果为阳性;52株其他菌株的检测结果均为阴性;灵敏度实验结果显示考核试剂隐球菌最低检出限为1.0×102 CFU/mL;2 M和4 M浓度菌液均未出现钩状效应。结论考核试剂隐球菌荚膜多糖检测试剂盒(胶体金法)检测隐球菌属的灵敏度高于比对试剂;特异性方面存在一定的属内和属外交叉反应,但与对比试剂的检测结果高度一致;考核试剂与比对试剂均无钩状效应产生。 相似文献
4.
《Clinical neurophysiology》2021,132(6):1312-1320
ObjectiveTo investigate the additional value of EEG functional connectivity features, in addition to non-coupling EEG features, for outcome prediction of comatose patients after cardiac arrest.MethodsProspective, multicenter cohort study. Coherence, phase locking value, and mutual information were calculated in 19-channel EEGs at 12 h, 24 h and 48 h after cardiac arrest. Three sets of machine learning classification models were trained and validated with functional connectivity, EEG non-coupling features, and a combination of these. Neurological outcome was assessed at six months and categorized as “good” (Cerebral Performance Category [CPC] 1–2) or “poor” (CPC 3–5).ResultsWe included 594 patients (46% good outcome). A sensitivity of 51% (95% CI: 34–56%) at 100% specificity in predicting poor outcome was achieved by the best functional connectivity-based classifier at 12 h after cardiac arrest, while the best non-coupling-based model reached a sensitivity of 32% (0–54%) at 100% specificity using data at 12 h and 48 h. Combination of both sets of features achieved a sensitivity of 73% (50–77%) at 100% specificity.ConclusionFunctional connectivity measures improve EEG based prediction models for poor outcome of postanoxic coma.SignificanceFunctional connectivity features derived from early EEG hold potential to improve outcome prediction of coma after cardiac arrest. 相似文献
5.
6.
《Clinical neurophysiology》2021,132(1):157-164
ObjectiveEarly EEG contains reliable information for outcome prediction of comatose patients after cardiac arrest. We introduce dynamic functional connectivity measures and estimate additional predictive values.MethodsWe performed a prospective multicenter cohort study on continuous EEG for outcome prediction of comatose patients after cardiac arrest. We calculated Link Rates (LR) and Link Durations (LD) in the α, δ, and θ band, based on similarity of instantaneous frequencies in five-minute EEG epochs, hourly, during 3 days after cardiac arrest. We studied associations of LR and LD with good (Cerebral Performance Category (CPC) 1–2) or poor outcome (CPC 3–5) with univariate analyses. With random forest classification, we established EEG-based predictive models. We used receiver operating characteristics to estimate additional values of dynamic connectivity measures for outcome prediction.ResultsOf 683 patients, 369 (54%) had poor outcome. Patients with poor outcome had significantly lower LR and longer LD, with largest differences 12 h after cardiac arrest (LRθ 1.87 vs. 1.95 Hz and LDα 91 vs. 82 ms). Adding these measures to a model with classical EEG features increased sensitivity for reliable prediction of poor outcome from 34% to 38% at 12 h after cardiac arrest.ConclusionPoor outcome is associated with lower dynamics of connectivity after cardiac arrest.SignificanceDynamic functional connectivity analysis may improve EEG based outcome prediction. 相似文献
7.
8.
ObjectivesWe evaluated breast cancer (BC) care quality indicators (QIs) in clinical pathways and integrated health care processes.MethodsFollowing protocol registration (Prospero no: CRD42021228867), relevant documents were identified, without language restrictions, through a systematic search of bibliographic databases (EMBASE, Scopus, Web of Science, MEDLINE), health care valuable representatives and the World Wide Web in April 2021. Data concerning QIs, measurement tools and compliance standards were extracted from European and North American sources in duplicate with 98% reviewer agreement.ResultsThere were 89 QIs found from 22 selected documents (QI per document mean 13.5 with standard deviation 11.9). The Belgian (38 QIs) and the EUSOMA (European Society of Breast Cancer Specialists) (34 QIs) documents were the ones that best reported the QIs. No identical QI was identified in all the documents analysed. There were 67/89 QIs covering processes (75.3%) and 11/89 (12.4%) for each structure and outcomes QIs. There were 21/89 QIs for diagnosis (30.3%), 43/89 for treatment (48.3%), and 19/89 for staging, counselling, follow-up and rehabilitation (21.4%). Of 67 process QIs and 11 outcome QIs, 20/78 (26%) did not report a minimum standard of care. Shared decision making was only included as a QI in the Italian document.ConclusionMore than half of countries have not established a national clinical pathway or integrated breast cancer care process to achieve the excellence of BC care. There was heterogeneity in QIs for the evaluation of BC care quality. Over two-thirds of the clinical pathways and integrated health care processes did not provide a minimum auditable standard of care for compliance, leaving open the definition of best practice. There is a need for harmonisation of BC care QIs. 相似文献
9.
摘要:目的对尿液 10项肾损伤标志物检测试剂进行性能评价,并评估其临床适用性。方法对北京利德曼公司尿液a1 微球蛋白(u-a|MG)、总蛋白(u-TP)、免疫球蛋白G(u-IgG) 、微量清蛋白(u-Alb)、中性粒细胞明胶酶相关脂质运载蛋白(u-NGAL)、半胱氨酸蛋白酶抑制剂C(u-CysC).视黄醇结合蛋白(u-RBP)、β2微球蛋白(u-β2MG)、N-乙酰-β-D-氨基葡萄糖苷酶(u-NAG).、转铁蛋白(u-Trf)检测试剂盒进行性能评价。正确度和精密度验证参考美国临床和实验室标准协会(CLSI)EP15-A3,验证物质采用ERM-DA470k、ERM-DA471、B2M-NIBSC等参考物质及纯度物质;线性验证参考CLSI EP06;抗干扰能力参考CISI EP07;不同检测系统间比对参考CISI EP09。结果正确度方面,10 项标志物检测试剂测定标准物质在低值、中值、高值的偏倚分别为-2.69% ~4.67%、-3.60% ~3.33% .-2.38% ~3.02%;不精密度方面,重复性以不精密度表示,在低值和高值处分别为1.90%~5.43%、0.63% ~2.42%,室内不精密度为2.27%~5.63%、1.09%~3.41%,均满足临床要求;10项尿液标志物线性范围在0.06~4.40 mg/L至21.83~2 146.77 mg/L之间。抗干扰方面,u-1 MG、u-Alb、u-β2MG、u-Trf 、u-CysC、u-NAG分别在血红蛋白终浓度≤8 g/L、≤8 g/L、≤4 g/L、≤4 g/L、≤2g/L、≤1 g/L时,未受到明显干扰(百分偏差≤+ 10%) ,而u-TP、u-IgG、
u-RBP、u-NGAL在血红蛋白终浓度≥0.125 g/L时即受干扰。不同检测系统间偏差超出临床允许范围。结论尿液 10项肾损伤标志物的正确度、精密度、线性范围和抗血红蛋白干扰能力满足临床需要,不同检测系统间标志物测量结果可比性欠佳。 相似文献
10.
《Clinical oncology (Royal College of Radiologists (Great Britain))》2022,34(7):472-479
AimsTreatment decisions for older patients with breast cancer are complex and evidence is largely extrapolated from younger populations. Frailty and comorbidity need to be considered. We studied the baseline characteristics and treatment decisions in older patients in Christchurch with breast cancer and assessed survival outcomes and prognostic/discriminatory performance of several tools.Materials and methodsWe searched the Canterbury Breast Cancer Registry and identified patients aged 70 years or older at diagnosis with invasive, non-metastatic breast cancer between 1 June 2009 and 30 June 2015. We retrieved demographics, treatment and outcome information. Overall survival and breast cancer-specific survival were estimated. Tools analysing performance status and comorbidity were assessed for their prognostic and discriminatory power.ResultsIn total, 440 patients were identified. Primary surgery was carried out for 362 patients (82.3%): breast-conserving surgery in 114 (of whom 88.6% received radiation therapy); mastectomy in 248 (of whom 24.6% received radiation). Hormone therapy was given for 265 (71.1%) patients with oestrogen receptor-positive cancers. Two hundred and seventy-four (62.3%) patients received full standard treatment, which was associated with significantly improved 5-year survival and 5-year breast cancer-specific survival. The median estimated overall survival was 8.2 years (95% confidence interval 7.3–9.1 years). Of those who died, 71.3% of deaths were due to causes other than breast cancer or unknown causes. The comorbidity-adjusted life expectancy (CALE) showed partial prognostic accuracy. CALE, Charlson and Eastern Cooperative Oncology Group tools all showed discriminatory value.ConclusionIn this population-based series of older patients with breast cancer, showing high levels of primary and adjuvant treatment, patients were more likely to die of causes other than breast cancer. Performance status and comorbidity tools showed prognostic and discriminatory potential in this population supporting their use in treatment decision making. CALE showed the most potential to improve treatment decisions but requires validation in this population to improve prognostic accuracy. 相似文献